Multicenter phase II trial of single-dose carboplatin followed by involved-node radiotherapy for stage IIA and stage IIB seminoma

Standard treatment options for patients with stage IIA or stage IIB seminoma include either para-aortic and pelvic radiotherapy or three to four cycles of cisplatin-based combination therapy. These options result in 3-year progression-free survival rates of at least 90%, but bear risks for acute and late toxic effects, including secondary malignancies. The phase 2 SAKK 01/10 trial in Switzerland and Germany found a favorable 3-year PFS rate (93.7%) and minimal toxic effects with single-dose carboplatin AUC 7 and involved-node radiotherapy for stage IIA and stage IIB seminoma.